Clinical Trials Browser

Phase 2 × fosaprepitant × Tumor-Agnostic × Clear all

NCT04508400 2024-01-09

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Phase 2 Completed

Neoplasms